Oryzon Genomics (Spain) Performance
| ORY Stock | EUR 1.58 0.04 2.60% |
The company holds a Beta of -0.18, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Oryzon Genomics are expected to decrease at a much lower rate. During the bear market, Oryzon Genomics is likely to outperform the market. At this point, Oryzon Genomics SA has a negative expected return of -0.27%. Please make sure to check Oryzon Genomics' accumulation distribution, as well as the relationship between the day median price and period momentum indicator , to decide if Oryzon Genomics SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Oryzon Genomics SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 39.6 M | |
| Total Cashflows From Investing Activities | -11.7 M |
Oryzon |
Oryzon Genomics Relative Risk vs. Return Landscape
If you would invest 189.00 in Oryzon Genomics SA on September 12, 2024 and sell it today you would lose (31.00) from holding Oryzon Genomics SA or give up 16.4% of portfolio value over 90 days. Oryzon Genomics SA is producing return of less than zero assuming 1.428% volatility of returns over the 90 days investment horizon. Simply put, 12% of all stocks have less volatile historical return distribution than Oryzon Genomics, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Oryzon Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oryzon Genomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oryzon Genomics SA, and traders can use it to determine the average amount a Oryzon Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1888
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ORY |
Estimated Market Risk
| 1.43 actual daily | 12 88% of assets are more volatile |
Expected Return
| -0.27 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Oryzon Genomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oryzon Genomics by adding Oryzon Genomics to a well-diversified portfolio.
Oryzon Genomics Fundamentals Growth
Oryzon Stock prices reflect investors' perceptions of the future prospects and financial health of Oryzon Genomics, and Oryzon Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oryzon Stock performance.
| Return On Equity | -0.0685 | |||
| Return On Asset | -0.0419 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.72) % | |||
| Current Valuation | 107.12 M | |||
| Shares Outstanding | 55.56 M | |||
| Price To Earning | (12.98) X | |||
| Price To Book | 1.65 X | |||
| Price To Sales | 12.17 X | |||
| EBITDA | (6.58 M) | |||
| Cash And Equivalents | 29.11 M | |||
| Cash Per Share | 0.76 X | |||
| Total Debt | 10.35 M | |||
| Debt To Equity | 37.10 % | |||
| Book Value Per Share | 1.35 X | |||
| Cash Flow From Operations | (3.63 M) | |||
| Earnings Per Share | (0.09) X | |||
| Total Asset | 95.38 M | |||
About Oryzon Genomics Performance
By analyzing Oryzon Genomics' fundamental ratios, stakeholders can gain valuable insights into Oryzon Genomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Oryzon Genomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oryzon Genomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. Oryzon Genomics S.A. was founded in 2000 and is based in Barcelona, Spain. ORYZON GENOMICS operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 40 people.Things to note about Oryzon Genomics SA performance evaluation
Checking the ongoing alerts about Oryzon Genomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oryzon Genomics SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oryzon Genomics SA generated a negative expected return over the last 90 days | |
| Oryzon Genomics SA may become a speculative penny stock | |
| Net Loss for the year was (4.69 M) with profit before overhead, payroll, taxes, and interest of 9.87 M. | |
| Oryzon Genomics SA has accumulated about 29.11 M in cash with (3.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Roughly 18.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Oryzon Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oryzon Genomics' stock is overvalued or undervalued compared to its peers.
- Examining Oryzon Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oryzon Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oryzon Genomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oryzon Genomics' stock. These opinions can provide insight into Oryzon Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Oryzon Stock analysis
When running Oryzon Genomics' price analysis, check to measure Oryzon Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oryzon Genomics is operating at the current time. Most of Oryzon Genomics' value examination focuses on studying past and present price action to predict the probability of Oryzon Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oryzon Genomics' price. Additionally, you may evaluate how the addition of Oryzon Genomics to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |